SAbDab: The Structural Antibody Database

> Structural Summary

Therapeutic	Volagidemab
Target	GCCR/NR3C1
Heavy Chain	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	4ers [Fvs: HL], 4lf3 [Fvs: BA, ED], 5xez [Fvs: CD, HL], 5xf1 [Fvs: CD, HL]
95-98% seqID Fv Structure	None

> SAbDab Links

99% seqID Structure	4lf3 [Fvs: BA, ED]
99% seqID Structure	5xf1 [Fvs: CD, HL]
99% seqID Structure	5xez [Fvs: CD, HL]
99% seqID Structure	4ers [Fvs: HL]
There are no identical PDB matches to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Volagidemab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

> 4lf3: B/A

Sequence identity: 99.57%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	100G	100H	100I	100J	100K	101	102	103	104	105	106	107	108	109	110	111	112	113
volagidemab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	W	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S
4lf3	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	W	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
volagidemab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K
4lf3	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	E	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K

> 5xf1: C/D

Sequence identity: 99.15%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	100G	100H	100I	100J	100K	101	102	103	104	105	106	107	108	109	110	111	112	113
volagidemab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	W	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S
5xf1	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	Y	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
volagidemab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K
5xf1	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	E	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K

> 5xez: C/D

Sequence identity: 99.15%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	100G	100H	100I	100J	100K	101	102	103	104	105	106	107	108	109	110	111	112	113
volagidemab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	W	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S
5xez	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	Y	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
volagidemab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K
5xez	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	E	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K

> 4ers: H/L

Sequence identity: 99.15%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	100G	100H	100I	100J	100K	101	102	103	104	105	106	107	108	109	110	111	112	113
volagidemab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	W	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S
4ers	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	S	Y	G	M	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	V	M	Y	Y	D	G	S	N	K	D	Y	V	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	R	L	R	A	E	D	T	A	V	Y	Y	C	A	R	E	K	D	H	Y	D	I	L	T	G	Y	N	Y	Y	Y	G	L	D	V	W	G	Q	G	T	T	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
volagidemab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K
4ers	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	G	I	R	N	D	L	G	W	Y	Q	Q	K	P	G	K	A	P	K	R	L	I	Y	A	A	S	S	L	E	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	V	Q	P	E	D	F	V	T	Y	Y	C	L	Q	H	N	S	N	P	L	T	F	G	G	G	T	K	V	E	I	K

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

> Metadata

Format	Whole mAb
Isotype	G2
Highest Clinical Trial (Aug '24)	Phase-II
Estimated Status (Aug '24)	Active
Recorded Developmental Technology
INN Year Proposed	2018
INN Year Recommended	2019
Companies Involved	Amgen, REMD Biotherapeutics
Conditions Approved	na
Conditions Active	Type 1 diabetes mellitus, Type 2 diabetes mellitus, Metabolic disorders, Glucose intolerance
Conditions Discontinued	na
Notes

Thera-SAbDab

VOLAGIDEMAB